Early studies have shown that Aspirin is capable of inhibiting mTOR and protein kinase B (Akt) via adenosine monophosphate-activated protein kinase (AMPK)-dependent and non-AMPK-dependent pathways, inducing cellular autophagy, and thereby acting as an anticancer agent [34]; similarly, Meloxicam activated AMPK and inhibited mTOR phosphorylation in hepatocellular carcinoma cells [53]. Here, AKT1 is linked to hepatocellular carcinoma.